SonoTarg Ltd
Nigel Trim is an accomplished leader with 30 years of experience in the biotechnology and pharmaceutical industries, currently serving as the Chief Executive Officer of SonoTarg, focused on treating difficult cancers. Nigel's career includes roles as Principal at Rivendell Farm since 2011 and as Joint CEO and CSO at Isophene Ltd until December 2022. Previously, Nigel held positions such as Chairman at FRESH CHECK LTD. and Altair Clinical Ltd, as well as Managing Director at Accelovance, Inc. and Novella Clinical. A strong background in clinical development, Nigel has successfully navigated companies through significant changes and growth, emphasizing merger and acquisition activity. Educationally, Nigel holds a BSc Hons in Pharmacology from the University of Liverpool.
This person is not in any teams
SonoTarg Ltd
SonoTarg has developed a new approach to targeted cancer therapy that enables physicians to specifically activate therapeutics at the site of tumour and minimise the adverse effects associated with conventional chemotherapy. The technology is based on research co-developed between the Universities of Ulster and Oxford and in close collaboration with leading clinicians at Belfast Hospitals. Read more at www.sonotarg.com